Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO ^® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers

Abstract

Background

HCP1004 is a newly developed fixed-dose combination of naproxen (500 mg) and esomeprazole strontium (20 mg) that is used in the treatment of rheumatic diseases and can reduce the risk of nonsteroidal anti-inflammatory drug-associated ulcers. The aim of this study was to evaluate the pharmacokinetics (PK) and safety of HCP1004 compared to VIMOVO ^® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium).

Subjects and methods

An open-label, randomized, two-treatment, two-sequence crossover, single-dose clinical study was conducted in 70 healthy volunteers. In each period, a reference (VIMOVO ^®) or test (HCP1004) drug was administered orally, and serial blood samples for PK analysis were collected up to 72 hours after dosing. To evaluate the PK profiles, the maximum plasma concentration (C _max) and the area under the concentration–time curve from 0 to the last measurable time (AUC _0−t) were estimated using a noncompartmental method. Safety profiles were evaluated throughout the study.

Results

Sixty-six of the 70 subjects completed the study. The C _max (mean ± standard deviation) and AUC _0−t (mean ± standard deviation) for naproxen in HCP1004 were 61.67±15.16 µg/mL and 1,206.52±166.46 h·µg/mL, respectively; in VIMOVO ^®; these values were 61.85±14.54 µg/mL and 1,211.44±170.01 h·µg/mL, respectively. The C _max and AUC _0−t for esomeprazole in HCP1004 were 658.21±510.91 ng/mL and 1,109.11±1,111.59 h·ng/mL, respectively; for VIMOVO ^®, these values were 595.09±364.23 ng/mL and 1,015.12±952.98 h·ng/mL, respectively. The geometric mean ratios and 90% confidence intervals (CIs) (HCP1004 to VIMOVO ^®) of the C _max and AUC _0−t of naproxen were 0.99 (0.94–1.06) and 1.00 (0.98–1.01), respectively. For esomeprazole, the geometric mean ratios (90% CI) for the C _max and AUC _0−t were 0.99 (0.82–1.18) and 1.04 (0.91–1.18), respectively. The overall results of the safety assessment showed no clinically significant issues for either treatment.

Conclusion

The PK of HCP1004 500/20 mg was comparable to that of VIMOVO ^® 500/20 mg for both naproxen and esomeprazole after a single oral dose. Both drugs were well-tolerated without any safety issues.